ASH 2022 | Phase I study of CART-ddBCMA in R/R multiple myeloma
Michael Bishop, MD, University of Chicago, Chicago, IL, shares insights on the results of a Phase I trial (NCT04155749) that investigated the use of CART-ddBCMA in patients with relapsed/refractory (R/R) multiple myeloma. Prof. Bishop explains that the preliminary results for this trial are highly promising; with response rates at 100%, high rates of measurable residual disease (MRD) negativity, and acceptable toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Honoraria, Other: Travel support, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: Travel support , Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Agios: Consultancy, Honoraria, Other: Travel support, Speakers Bureau; Iovance: Consultancy; Bluebird Bio: Consultancy; WindMIL Therapeutics: Consultancy; Arcellx: Consultancy, Research Funding; Autolus: Consultancy, Research Funding; Immatics: Research Funding; Triumvira: Research Funding; Tmunity: Research Funding; Chimeric Therapeutics: Consultancy; Sanofi: Honoraria, Speakers Bureau; Sana Biotechnology: Consultancy; Servier: Speakers Bureau; ADC Therapeutics: Speakers Bureau; Celgene: Honoraria; Incyte: Honoraria, Other: Travel support , Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel support, Research Funding, Speakers Bureau.
